Literature DB >> 14631616

Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia.

Kudret Cağlar1, Ahmet Cetinkaya, Selin Aytaç, Fatma Gümrük, Aytemiz Gürgey.   

Abstract

Glanzmann thrombasthenia is a very rare inherited platelet function disorder in which bleeding may be extremely difficult to stop. Recombinant factor VIIa is one of the alternative treatments for bleeding. The authors report here their experience with the use of factor VIIa, which may be useful for arresting bleeding in Glanzmann thrombasthenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14631616

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  4 in total

Review 1.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 2.  The use of recombinant activated factor VII in platelet disorders: a critical review of the literature.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2009-01       Impact factor: 3.443

3.  An in vitro evaluation of standard rotational thromboelastography in monitoring of effects of recombinant factor VIIa on coagulopathy induced by hydroxy ethyl starch.

Authors:  Martin Engström; Peter Reinstrup; Ulf Schött
Journal:  BMC Blood Disord       Date:  2005-02-15

Review 4.  Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.

Authors:  Man-Chiu Poon
Journal:  Vasc Health Risk Manag       Date:  2007
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.